Gregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $12.82, for a total transaction of $128,200.00. Following the transaction, the insider now owns 122,279 shares in the company, valued at $1,567,616.78. This represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Centessa Pharmaceuticals Trading Up 0.5%

NASDAQ:CNTA traded up $0.07 during mid-day trading on Friday, hitting $13.14. 751,590 shares of the stock traded hands, compared to its average volume of 655,860. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -8.59 and a beta of 1.53. Centessa Pharmaceuticals plc has a 52 week low of $7.90 and a 52 week high of $19.09. The firm's 50 day moving average is $12.78 and its two-hundred day moving average is $15.38.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.15. On average, equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Morgan Stanley restated an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Oppenheimer started coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They set an "outperform" rating and a $6.00 price target on the stock. Guggenheim reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Needham & Company LLC began coverage on Centessa Pharmaceuticals in a research report on Wednesday. They set a "buy" rating and a $35.00 price objective for the company. Finally, Wall Street Zen raised Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $27.89.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CNTA. GF Fund Management CO. LTD. bought a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $31,000. Caitong International Asset Management Co. Ltd increased its position in shares of Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after acquiring an additional 3,194 shares during the period. Osterweis Capital Management Inc. acquired a new position in shares of Centessa Pharmaceuticals in the first quarter valued at about $47,000. Barclays PLC increased its holdings in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in shares of Centessa Pharmaceuticals during the first quarter worth $147,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.